Alprazolam Tablets 1mg Recalled for CGMP Deviations
Preferred Pharmaceuticals is recalling 276 bottles of Alprazolam Tablets USP 1mg (generic Xanax) distributed nationwide due to Current Good Manufacturing Practice (CGMP) deviations. The recall was initiated voluntarily by the manufacturer.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall initiated voluntarily for CGMP deviations. No illnesses, injuries, or specific product defects are reported in the source text. The source text does not indicate any actual harm or high-risk contamination, making this a precautionary manufacturing quality recall rather than a direct safety hazard.
Plain-English summary
Preferred Pharmaceuticals, Inc. is voluntarily recalling Alprazolam Tablets, USP 1mg (a generic form of Xanax) in three package sizes: 30-tablet bottles (NDC 68788-6381-03), 60-tablet bottles (NDC 68788-6381-06), and 90-tablet bottles (NDC 68788-6381-09). A total of 276 bottles have been distributed nationwide in the USA. The recall was initiated on February 22, 2022, and was classified by the FDA as Class II.
The reason for the recall is Current Good Manufacturing Practice (CGMP) deviations identified in the manufacturing process. The affected lot numbers are: G2919M, I0619O, and F1419J (30-tablet bottles); H3019Q (60-tablet bottles); and F1219N, F1919D, H0219D, I0519R, and J0319G (90-tablet bottles), all with an expiration date of March 31, 2022.
Consumers who have purchased this medication should stop use and consult with their pharmacy or healthcare provider about next steps, including potential replacement medication or refunds. The FDA classified this recall as Class II because it is a voluntary, firm-initiated recall for manufacturing deviations that could result in drug quality issues.
The recalled product
- Product
- Alprazolam Tablets, USP 1mg, Generic for Xanax, Pkg Size: a) 30 tablets per bottle, NDC: 68788-6381-03, b) 60 tablets per bottle, NDC: 68788-6381-06, c) 90 tablets per bottle, NDC: 68788-6381-09, Mfg: Par Pharmaceutical.
- Manufacturer
- Preferred Pharmaceuticals, Inc.
- Category
- Drug — Benzodiazepine
- Hazard
- Affected units
- 276
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (10)
- Lot #s: a) G2919M
- I0619O
- F1419J
- b) H3019Q
- c) F1219N
- F1919D
- H0219D
- I0519R
- J0319G
- Exp. 03/31/2022.
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Preferred Pharmaceuticals, Inc.
See all →- HighGeri-Care artificial tears lubricant eye drops recalled over sterility assurance
FDA (Drugs) · 2026-04-15
- ModerateOndansetron blister packs recalled because tablets are falling out
FDA (Drugs) · 2025-12-24
- ModerateClindamycin Hydrochloride Capsules Recalled for cGMP Deviations
FDA (Drugs) · 2025-05-07
- HighIbuprofen Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-09-04
- HighDuloxetine Delayed-Release Capsules Recalled for Nitrosamine Impurity
FDA (Drugs) · 2024-05-29
Same hazard · manufacturing deviation
See all →- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06